News

Read our latest news, and find more about us and our portfolio companies.

2021/05/17
Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures

Proceeds to fund early pipeline of novel switchable bispecific T-cell engagers to treat solid tumor cancers Company's proprietary T-LITE platform based on small molecule-dependent activation of T-cell engagers, enabling potentially safer and more efficacious tumor targeted therapy Seasoned leadership to steer company's growth and pipeline development

2021/04/22
Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators

Seed round was led by M Ventures and INKEF Capital, and co-led by Taiho Ventures and Bioqube Ventures

2021/04/01
FoRx Therapeutics AG appoints Tarig Bashir as Chief Executive Officer

FoRx Therapeutics announces the appointment of Tarig Bashir as Chief Executive Officer

2021/03/08
STORM Therapeutics Expands Scientific Advisory Board with the Appointment of Professor Tsutomu Suzuki

STORM Therapeutics today announces the appointment of Professor Tsutomu Suzuki to its Scientific Advisory Board (SAB)

2021/03/03
FORENDO PHARMA SUCCESSFULLY COMPLETES PHASE 1 STUDIES OF FOR-6219 IN ENDOMETRIOSIS, AIMING TO ADVANCE PROGRAM INTO PHASE 2 CLINICAL STUDIES

Forendo Pharma today announced the completion of Phase 1 studies in healthy volunteers for its lead development program in endometriosis, FOR-6219, and provided a development outlook

2021/02/24
Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline

• Deal led by Rock Springs Capital and joined by Bain Capital Life Sciences, Deerfield Management, RA Capital Management and other investors • Proceeds will advance XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4) into the clinic • Two investigational new drug (IND) applications planned in 2021

2021/02/11
Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients

* Artios Pharma transitions to a clinical-stage precision medicine company * Advances next generation DNA Damage Response (DDR) treatment targeting ATR in patients with advanced or metastatic solid tumors

2021/01/21
Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders

Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders - Company also announces appointment of biotech veteran Mike Grey as Chairman of the Board